Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - turoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - turoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - turoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - the administration set is to be used for injection (administration) of novo nordisk factor products and contains: 1 sterile infusion set (tubing and butterfly with needle protection), 2 sterile alcohol swabs, 2 sterile gauze pads and 2 sterile plasters

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - intended to deliver novo nordisk insulin products packaged in a 3 ml penfill® cartridge and used together with novofine® needles.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 1mg - powder for injection with diluent - 1 mg - active: eptacog alfa (activated) 1mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 2mg - powder for injection with diluent - 2 mg - active: eptacog alfa (activated) 2mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 5mg - powder for injection with diluent - 5 mg - active: eptacog alfa (activated) 5mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 8mg;   - powder for injection with diluent - 8 mg - active: eptacog alfa (activated) 8mg   excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions